Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Cyramza Shows Promise In First-Line NSCLC – But Not Much Room To Grow

Executive Summary

Studied with Tarceva, Cyramza showed an ability to improve PFS in patients with EGFR-mutant tumors. But how will a two-company combo fare against Tagrisso monotherapy?

Advertisement

Related Content

Lilly's New Year Resolution: Make New Launches Into Blockbusters
New EU Approval Further Boost For Tagrisso As Threats Recede
RAINFALLs On Lilly's Cyramza Stomach Cancer Parade
R&D In Brief: Lilly’s Cyramza Cleared In Lung, SABCS & ASH Updates

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124895

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel